{
    "pubmed_id": 34260834,
    "study_identifier": "PMID34260834_study-01",
    "study_name": "Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination",
    "publication_title": "Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination",
    "study_objective": "To evaluate the 8-month durability of humoral and cellular immune responses after Ad26.COV2.S Vaccination",
    "study_description": "These data show that the Ad26.COV2.S vaccine elicited durable humoral and cellular immune responses with minimal decreases for at least 8 months after immunization. In addition, we observed an expansion of neutralizing antibody breadth against SARS-CoV-2 variants over this time period, including against the more transmissible B.1.617.2 variant and the partially neutralization-resistant B.1.351 and P.1 variants, which suggests maturation of B-cell responses even without further boosting. The durability of immune responses elicited by the Ad26.COV2.S vaccine was consistent with the durability recently reported for an Ad26-based Zika vaccine.4 Longitudinal antibody responses to mRNA Covid-19 vaccines have also been reported for 6 months but with different kinetics of decreasing titers.5 The durability of humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination with increased neutralizing antibody responses to SARS-CoV-2 variants over time, including after single-shot vaccination, further supports the use of the Ad26.COV2.S vaccine to combat the global Covid-19 pandemic.",
    "primary_institution_name": "Harvard University",
    "study_personnel": [
        {
            "personnel_id": "PMID34260834_personnel-01",
            "honorific": "",
            "last_name": "Barouch",
            "first_name": "Dan",
            "suffixes": "",
            "organization": "Harvard University",
            "orchid_id": "",
            "email": "dbarouch@bidmc.harvard.edu",
            "seronet_title_in_study": "SeroNet Principal Investigator",
            "role_in_study": "Principal Investigator",
            "site_name": "Harvard University"
        }
    ],
    "study_file": [
        {
            "study_file_name": "PMID-34260834_Fig.1A_01-05-22.xlsx",
            "study_file_description": "Study Data",
            "study_file_type": "Study Data"
        },
        {
            "study_file_name": "PMID-34260834_Fig.1B_01-05-22.xlsx",
            "study_file_description": "Study Data",
            "study_file_type": "Study Data"
        },
        {
            "study_file_name": "PMID-34260834_Fig.1C_01-05-22.xlsx",
            "study_file_description": "Study Data",
            "study_file_type": "Study Data"
        },
        {
            "study_file_name": "NEJMc2108829_appendix.pdf",
            "study_file_description": "Study Data",
            "study_file_type": "Study Data"
        },
        {
            "study_file_name": "NEJMc2108829_disclosures.pdf",
            "study_file_description": "Disclosures",
            "study_file_type": "Study Summary Description"
        },
        {
            "study_file_name": "PMID34260834_v1.2.3.xlsm",
            "study_file_description": "Completed curation of the study into SeroNet Registry Template which includes SeroNet Study Descriptors.",
            "study_file_type": "Study Summary Description"
        }
    ],
    "study_link": [],
    "research_focus": "Vaccine Response",
    "study_type": "Clinical Research",
    "keyword": [
        "Ad26COVS1",
        "Antibodies Neutralizing blood",
        "Antibodies Viral blood",
        "COVID-19 Vaccines immunology",
        "Follow-Up Studies",
        "Humans",
        "Immunity Cellular",
        "Immunity Humoral",
        "Immunogenicity Vaccine",
        "SARS-CoV-2",
        "T-Lymphocytes physiology",
        "Vaccination"
    ],
    "clinical_study_design": "Prospective Cohort",
    "in_silico_model_type": "",
    "protocol": {
        "protocol_id": "PMID34260834_protocol-01",
        "protocol_file_name": "PMID34260834_protocol-01.txt",
        "protocol_name": "PMID34260834_protocol-01",
        "protocol_description": "Study Protocol",
        "protocol_type": "Study Protocol"
    },
    "reported_health_condition": [
        "Covid-19"
    ],
    "sars_cov_2_vaccine_type": [
        "Johnson & Johnson"
    ],
    "clinical_outcome_measure": "Humoral and cellular immune responses after Ad26.COV2.S Vaccination",
    "enrollment_start_date": "",
    "enrollment_end_date": "",
    "number_of_study_subjects": 25,
    "age_unit": "Years",
    "minimum_age": "",
    "maximum_age": "",
    "study_human_cohort": [
        {
            "arm_id": "PMID34260834_human_subject-01",
            "arm_name": "Participants received single dose of Ad26.COV2.S vaccine",
            "study_population_description": "10 participants received single dose of (5\u00d71010 viral particles) Ad26.COV2.S vaccine",
            "arm_type": "Vaccination",
            "ethnicity": [
                "Not Specified"
            ],
            "race": [
                "Not Specified"
            ],
            "race_specify": [],
            "description": "",
            "sex_at_birth": [
                "Not specified"
            ],
            "age_event": "Not Specified",
            "subject_phenotype": "",
            "assessment_name": [],
            "study_location": [
                "US: Massachusetts"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [
                "Vaccinated"
            ],
            "sars_cov_2_vaccine_type": [
                "Johnson & Johnson COVID-19 vaccine; VO:0005159"
            ],
            "covid_19_disease_severity": [],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        },
        {
            "arm_id": "PMID34260834_human_subject-02",
            "arm_name": "Participants received two doses of Ad26.COV2.S vaccine",
            "study_population_description": "10 participants received two doses of ( 1011 viral particles) Ad26.COV2.S vaccine",
            "arm_type": "Vaccination",
            "ethnicity": [
                "Not Specified"
            ],
            "race": [
                "Not Specified"
            ],
            "race_specify": [],
            "description": "",
            "sex_at_birth": [
                "Not specified"
            ],
            "age_event": "Not Specified",
            "subject_phenotype": "",
            "assessment_name": [],
            "study_location": [
                "US: Massachusetts"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [
                "Vaccinated"
            ],
            "sars_cov_2_vaccine_type": [
                "Johnson & Johnson COVID-19 vaccine; VO:0005159"
            ],
            "covid_19_disease_severity": [],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        },
        {
            "arm_id": "PMID34260834_human_subject-03",
            "arm_name": "Participants received placebo",
            "study_population_description": "5 participants received placebo",
            "arm_type": "Placebo Comparator Arm",
            "ethnicity": [
                "Not Specified"
            ],
            "race": [
                "Not Specified"
            ],
            "race_specify": [],
            "description": "",
            "sex_at_birth": [
                "Not specified"
            ],
            "age_event": "Not Specified",
            "subject_phenotype": "",
            "assessment_name": [],
            "study_location": [
                "US: Massachusetts"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [],
            "sars_cov_2_vaccine_type": [],
            "covid_19_disease_severity": [],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        }
    ],
    "study_model_cohort": [],
    "planned_visit": [
        {
            "visit_id": "PMID34260834_visit-01",
            "visit_name": "Neutralizing Antibody Responses measured on day 29 in vaccine and placebo recipients",
            "visit_order_number": 1,
            "visit_min_start_day": 29,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID34260834_visit-02",
            "visit_name": "Vaccine administered to participants with two doses of vaccine or T cell response. Binding antibody titer was measured",
            "visit_order_number": 2,
            "visit_min_start_day": 1,
            "visit_max_start_day": 57,
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID34260834_visit-03",
            "visit_name": "The median binding antibody titer against the WA1/2020 receptor-binding domain measured on day 71 in vaccine recipients",
            "visit_order_number": 4,
            "visit_min_start_day": 71,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID34260834_visit-04",
            "visit_name": "T cell response was measured on day 85 in vaccine recipients",
            "visit_order_number": 5,
            "visit_min_start_day": 85,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID34260834_visit-05",
            "visit_name": "T cell response was measured on day 180 in participants who received two doses of vaccine",
            "visit_order_number": 6,
            "visit_min_start_day": 180,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID34260834_visit-06",
            "visit_name": "T cell response and the median binding antibody titer was measured on day 239 in single shot recipients",
            "visit_order_number": 7,
            "visit_min_start_day": 239,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        }
    ],
    "experiment": [
        {
            "arm_id": [
                "PMID34260834_human_subject-01",
                "PMID34260834_human_subject-02",
                "PMID34260834_human_subject-03"
            ],
            "associated_first_planned_visit_id": [
                "PMID34260834_visit-01",
                "PMID34260834_visit-02",
                "PMID34260834_visit-03",
                "PMID34260834_visit-04",
                "PMID34260834_visit-05",
                "PMID34260834_visit-06"
            ],
            "assay_type": "Pseudovirus Neutralization Assay",
            "experiment_name": "Pseudovirus Neutralization Assay",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Serum"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination"
            ],
            "sars_cov_2_antigen": [
                "Receptor Binding Domain (RBD)"
            ],
            "assay_use": "",
            "manufacture": "",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2 Beta; B.1.351",
                "SARS-CoV-2 Gamma; P.1",
                "SARS-CoV-2 Delta; B.1.617.2",
                "SARS-CoV-2 Beta; B.1.351"
            ],
            "antibody_isotype": [
                "Other"
            ],
            "reporting_units": "",
            "assay_reporting_format": ""
        },
        {
            "arm_id": [
                "PMID34260834_human_subject-01",
                "PMID34260834_human_subject-02",
                "PMID34260834_human_subject-03"
            ],
            "associated_first_planned_visit_id": [
                "PMID34260834_visit-01",
                "PMID34260834_visit-02",
                "PMID34260834_visit-03",
                "PMID34260834_visit-04",
                "PMID34260834_visit-05",
                "PMID34260834_visit-06"
            ],
            "assay_type": "ELISA",
            "experiment_name": "ELISA",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Serum"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination"
            ],
            "sars_cov_2_antigen": [
                "Receptor Binding Domain (RBD)"
            ],
            "assay_use": "",
            "manufacture": "",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2 Beta; B.1.351",
                "SARS-CoV-2 Gamma; P.1",
                "SARS-CoV-2 Delta; B.1.617.2",
                "SARS-CoV-2 Beta; B.1.351"
            ],
            "antibody_isotype": [
                "IgG"
            ],
            "reporting_units": "",
            "assay_reporting_format": ""
        },
        {
            "arm_id": [
                "PMID34260834_human_subject-01",
                "PMID34260834_human_subject-02",
                "PMID34260834_human_subject-03"
            ],
            "associated_first_planned_visit_id": [
                "PMID34260834_visit-01",
                "PMID34260834_visit-02",
                "PMID34260834_visit-03",
                "PMID34260834_visit-04",
                "PMID34260834_visit-05",
                "PMID34260834_visit-06"
            ],
            "assay_type": "Flow Cytometry",
            "experiment_name": "Intracellular cytokine staining (ICS) assay",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Peripheral Blood Mononuclear Cell (PBMC)"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination"
            ],
            "sars_cov_2_antigen": [
                "Receptor Binding Domain (RBD)"
            ],
            "assay_use": "",
            "manufacture": "",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2 Beta; B.1.351",
                "SARS-CoV-2 Gamma; P.1",
                "SARS-CoV-2 Delta; B.1.617.2",
                "SARS-CoV-2 Beta; B.1.351"
            ],
            "antibody_isotype": [
                "Other"
            ],
            "reporting_units": "",
            "assay_reporting_format": ""
        }
    ],
    "geriatric_subjects": "Not Specified",
    "pediatric_subjects": "Not Specified",
    "pregnant_subjects": "Not Specified",
    "sars_cov_2_antibodies_measured": "Yes",
    "survey_instrument_shared": "Not Specified",
    "who_disease_severity_scale_used": "Not Specified",
    "inclusion_exclusion": [
        {
            "inclusion_exculusion_id": "PMID34260834_inexcl-01",
            "inclusion_criterion": "SARS-CoV-2 Antibodies Measured",
            "inclusion_criterion_category": "inclusion"
        },
        {
            "inclusion_exculusion_id": "PMID34260834_inexcl-02",
            "inclusion_criterion": "Vaccine receipents",
            "inclusion_criterion_category": "inclusion"
        },
        {
            "inclusion_exculusion_id": "PMID34260834_inexcl-03",
            "inclusion_criterion": "mRNA vaccine recipients",
            "inclusion_criterion_category": "exclusion"
        },
        {
            "inclusion_exculusion_id": "PMID34260834_inexcl-04",
            "inclusion_criterion": "Subject with  SARS-CoV-2 infection",
            "inclusion_criterion_category": "exclusion"
        }
    ],
    "suggestions": [
        "8-month",
        "ad26-based",
        "ad26.cov2.s",
        "ad26covs1",
        "addition",
        "also",
        "antibodies",
        "antibodies neutralizing blood",
        "antibodies viral blood",
        "antibody",
        "b-cell",
        "b.1.351",
        "b.1.617.2",
        "boosting",
        "breadth",
        "cellular",
        "clinical",
        "cohort",
        "combat",
        "consistent",
        "covid-19",
        "covid-19 vaccines immunology",
        "data",
        "decreases",
        "decreasing",
        "different",
        "durability",
        "durable",
        "elicited",
        "evaluate",
        "even",
        "expansion",
        "follow-up studies",
        "global",
        "harvard",
        "humans",
        "humoral",
        "immune",
        "immunity cellular",
        "immunity humoral",
        "immunization",
        "immunogenicity vaccine",
        "including",
        "increased",
        "infection",
        "johnson & johnson",
        "kinetics",
        "least",
        "longitudinal",
        "maturation",
        "measured",
        "minimal",
        "months",
        "mrna",
        "neutralization-resistant",
        "neutralizing",
        "observed",
        "p.1",
        "pandemic",
        "partially",
        "period",
        "prospective",
        "receipents",
        "recently",
        "recipients",
        "reported",
        "research",
        "response",
        "responses",
        "sars-cov-2",
        "show",
        "single-shot",
        "subject",
        "suggests",
        "supports",
        "t-lymphocytes physiology",
        "time",
        "titers.5",
        "transmissible",
        "university",
        "use",
        "vaccination",
        "vaccine",
        "vaccine.4",
        "vaccines",
        "variant",
        "variants",
        "without",
        "zika"
    ]
}